NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may
control evasion of the immune response in tumors. The goal of this clinical trial is to
learn whether NPX267 is safe and tolerable in patients whose cancers are known to express
HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancer. The main questions it aims to answer are:
- what is an appropriate dose to be given to patients?
- are the side effects of treatment manageable?
Participants will be evaluated for participation in the study. Patients who are treated
will receive an intravenous infusion of NPX267 every three weeks if their disease has not
progressed. Patients will be closely monitored by the treating physician.
Additional locations may be listed on ClinicalTrials.gov for NCT05958199.
Locations matching your search criteria
United States
Maryland
Baltimore
Johns Hopkins University/Sidney Kimmel Cancer CenterStatus: Active
Name Not Available
This trial is divided into two parts. The first part (dose escalation) will test
different doses of drug to find a dose for part two. In the second part (dose expansion),
more patients will be tested to see if the drug has an effect on patient's tumors.
Throughout the study, data will be collected to characterize the clinical activity of the
drug. Samples of blood will be taken to help in an understanding of how the drug behaves
in the body by assessing the amount of drug in the blood over time (pharmacokinetics),
and changes in blood components (pharmacodynamics and safety). Tumor imaging by computed
tomography (CT) or magnetic resonance imaging (MRI) will be done about every nine weeks
to assess NPX267 impact on tumor growth.
Lead OrganizationNextPoint Therapeutics, Inc.
